Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action: (Clinical and Practical Psychopharmacolgy)
The DOI matches its Crossref record.
Abstract
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from conventional antidepressant drugs in that it brings about rapid and marked attenuation of depressive symptoms even in patients with refractory depression. The benefits are observed within hours of administration, peak after about a day, and are lost 3-12 days later. Patients who do not benefit after the initial dose may benefit with serial dosing or at higher doses. Benefits can be maintained for weeks to months by the continuation of ketamine sessions at 2- to 4-day intervals. Adverse effects include dissociative and psychotomimetic changes that are almost always mild and transient, if present; transient elevation of heart rate and blood pressure often occur. These changes are usually well tolerated and are very seldom responsible for treatment discontinuation. Whereas ketamine is an N-methyl-d-aspartate receptor antagonist, and whereas much is known about its different biological effects, its actions that mediate the antidepressant response are presently not known for certain. Although big data on ketamine are presently unavailable, the drug holds promise in the treatment of depression, es…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These acute and transient effects include an increase in blood pressure (usually asymptomatic), nausea and vomiting, perceptual disturbance, drowsiness, dizziness and dissociation.43,76–78”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [43]
In the citing paper
“Importantly, large head-to-head clinical comparisons of esketamine with R-ketamine and racemic ketamine have not yet been reported.41,43”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [43]
Citations
Cited by
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.007 · Cited by 246
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses
Kishi, T., Yoshimura, R., Ikuta, T., & Iwata, N. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00308 · Cited by 213
De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102888 · Cited by 174
Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.078 · Cited by 159
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Rong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 119
Ceban, F., Rosenblat, J. D., Kratiuk, K., Lee, Y. L., Rodrigues, N. B., Gill, H., Subramaniapillai, M., Nasri, F., Lui, L. M. W., Lipsitz, O., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00846-5 · Cited by 102
“Clinical trials, real-world case series, and a systematic review have established that most TEAEs are benign and transient, with onset occurring shortly after dosing, peaking in severity within 2 h, and resolving within 1–24 h [1, 4, 17].”
BackgroundBiological Mechanisms of Cancer-Induced Depression
Young, K., & Singh, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00299 · Cited by 87
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Riva-Posse, P., Reiff, C. M., Edwards, J. A., Job, G. P., Galendez, G. C., Garlow, S. J., Saah, T. C., Dunlop, B. W., & McDonald, W. M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.025 · Cited by 70
Dong, Y., Bo, T., Xue, X., Feng, C., Ren, Y., Ma, H., Zhang, J., Si, Y., Zhang, S., Liu, S., et al. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03389-w · Cited by 68
Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder
Gaspar, H. A., Gerring, Z. F., Hübel, C., Middeldorp, C. M., Derks, E. M., & Breen, G. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0451-4 · Cited by 54
“Ketamine, a member of the drug class of anesthetics, is used off-label for depression via intravenous infusions 44,45 ; our results suggest that its D2 partial agonism might be one possible explanation for its antidepressant effect, together with its serotonin and glutamate receptor antagonism 46…”
BackgroundThe evolutionary old forebrain as site of action to develop new psychotropic drugs
LOONEN, A. J. M., & Ivanova, S. А. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798617 · Cited by 41
“…treatment with a subanaesthetic dose of ketamine hydrochloride in seven depressed patients by Berman and colleagues (2000) the therapeutic effects of this N-methyl-D-aspartate receptor antagonist in patients with depression has been extensively studied (Andrade, 2017a, 2017b, 2017c, 2017d, 2017e).”
BackgroundBartlett, M. J., Flores, A. J., Ye, T., Smidt, S. I., Dollish, H. K., Stancati, J. A., Farrell, D. C., Parent, K. L., Doyle, K. P., Besselsen, D. G., et al. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113413 · Cited by 43
“…as an anesthetic since 1970, and has recently been repurposed at sub-anesthetic doses for the treatment of chronic pain (Niesters et al., 2014) and depression (Andrade, 2017), with S-ketamine now being an FDA approved drug for use in treatment-resistant depression (Kaufman, 2019).”
Influential5-HT1A receptor ligands and their therapeutic applications: review of new patents
Staroń, J., Bugno, R., Hogendorf, A. S., & Bojarski, A. J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1514011 · Cited by 35
“Additionally, the recent emergence of ketamine, which induces a rapid and sustainable antidepressant effect, has shifted attention to the glutamate system [88,89].”
BackgroundVeraart, J. K. E., Smith-Apeldoorn, S. Y., Spaans, H.-P., Kamphuis, J., & Schoevers, R. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.123 · Cited by 33
The Way to a Human’s Brain Goes Through Their Stomach: Dietary Factors in Major Depressive Disorder
Aly, J. S., & Engmann, O. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.582853 · Cited by 39
“However, due to its abuse potential, the use of ketamine is limited and not practicable as a long-term treatment (Andrade, 2017).”
BackgroundOral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence
Andrade, C. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19f12820 · Cited by 49
Self-citationTreatment of difficult-to-treat depression – clinical guideline for selected interventions
Møeller, S. B., Gbyl, K., Hjorthøj, C. R., Andreasen, M., Austin, S. F., Buchholtz, P. E., Fønss, L., Hjerrild, S., Hogervorst, L., Jørgensen, M. B., et al. (2021) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2021.1952303 · Cited by 32
Ye, T., Bartlett, M. J., Sherman, S. J., Falk, T., & Cowen, S. L. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113670 · Cited by 30
Recovery of cognitive functioning following abstinence from ketamine
Tang, W. K., Lau, C. G., Ungvari, G. S., Lin, S.-K., & Lane, H.-Y. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106081 · Cited by 23
Chan, L. F., Eu, C. L., Soh, S. Y., Maniam, T., Kadir, Z. S., Chong, B. T. W., Loo, J. L., Sharip, S., WONG, V. C. W., Loo, T. H., et al. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000316 · Cited by 20
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 23
“Both groups experienced significant reductions of severity of suicidality and were not significantly different.”
Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?
Cazet, L., Bulteau, S., Evin, A., Spiers, A., Caillet, P., Kuhn, E., Pivette, J., Chaslerie, A., Jolliet, P., & Victorri‐Vigneau, C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1496236 · Cited by 15
“However, the effects are lost 3 to 12 days after administration, which necessitates its off-label use and continuation of ketamine treatment every 2 to 4 days to maintain efficacy [57].”
BackgroundPsychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
“50 Recreational doses also fall far below those presented in preclinical studies.”
BackgroundKetamine induced cell death can be mediated by voltage dependent calcium channels in PC12 cells
Bustamante, J., Acosta, L. H., Karadayian, A. G., & Lores‐Arnaiz, S. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104318 · Cited by 13
Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review
Chen, Y., Magnin, C., Brunelin, J., Leaune, E., Fang, Y., & Poulet, E. (2021) · Brain and Behavior · doi:10.1002/brb3.2144 · Cited by 13
“However, lithium and ketamine, while effective, have various limitations such as drowsiness, dizziness, poor coordination, toxicity, and risk for dependency (Andrade, 2017; Zalsman et al., 2016).”
BackgroundIs PSD-95 entangled in the side effects of antidepressants?
Stachowicz, K. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105391 · Cited by 14
Hauser, J., Sarlon, J., Liwinski, T., Brühl, A. B., & Lang, U. E. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1327598 · Cited by 18
Wang, J., Zhao, Q., Zhou, Y., Sun, W., Han, S., Peng, Y., Li, J., & Han, R. (2019) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000610 · Cited by 13
“5 to 1mg/kg26; and (3) the most commonly used subanesthetic antidepressant dose of ketamine is a 40-minute infusion of 0.”
BackgroundGonçalves, C. L., Abelaira, H. M., Rosa, T., de Moura, A. B., Veron, D. C., Borba, L. A., Botelho, M. E. M., Goldim, M. P. D. S., Garbossa, L., Fileti, M. E., et al. (2021) · Pharmacological Reports · doi:10.1007/s43440-020-00200-4 · Cited by 12
Zhang, Y., Xie, B., Yuan, Y., Zhou, T., Xiao, P., Wu, Y., Shang, Y., Yuan, S., & Zhang, J. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.04.002 · Cited by 11
“The injection of exendin (9-39) was performed 15 minutes before (R,S)-ketamine injection.”
BackgroundMethodInfluentialSafety considerations and risk mitigation strategies for ketamine use: a comprehensive review
Sayad, R., Elsaeidy, A. S., Anis, A. M., Atef, M. M., Hawash, E. A., Saad, H. A., Hamad, K., & Kohaf, N. A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003232 · Cited by 10
“Bioavailability [ 94-96 ] Onset of action [ 93 ] Duration of action [ 93 ] Therapeutic applications [ 97-99 ] Safety and adverse effects [ 79 , 100-103 ] Intravenous combined with a Community of Practice (COP) framework [ 78 ] .”
Ketamine as anaesthesia for ECT: is there room to improve a gold standard treatment?
Andrade, C. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2017.15 · Cited by 11
Self-citationStopera, C. J., Bartlett, M. J., Liu, C., Esqueda, A., Parmar, R., Heien, M. L., Sherman, S. J., & Falk, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110047 · Cited by 13
“Low-dose ketamine treatment is FDA-approved for treatment-resistant depression, but has also been shown to be effective for other conditions such as post-traumatic stress disorder (PTSD) and chronic pain (Niesters et al., 2014; Feder et al., 2014; Andrade, 2017; Zanos et al., 2018).”
BackgroundChen, M., Su, T., Chen, L., Li, C., Wu, H.-J., Lin, W., Tsai, S., Bai, Y., Mao, W., Tu, P., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.010 · Cited by 10
A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry
Andrade, C., & Rao, T. S. (2017) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_345_17 · Cited by 9
Self-citationSteenblock, D. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.02.006 · Cited by 8
“The therapeutic effect when treating depression can be rapid, and reduction of suicidal ideation has been observed immediately following administration of the drug.(2) There are limited data available with respect to psychiatric treatment with ketamine in the elderly population, although some reports have described be…”
de Arruda, C. M., Doneda, D. L., de Oliveira, V. V., da Silva, R. A. L., de Matos, Y. A. V., Fernandes, I. L., Rohden, C. A. H., Viola, G. G., Rios-Santos, F., de Lima, E., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173433 · Cited by 9
Keith, K. M., Geller, J. A., Froehlich, A., Arfken, C. L., Oxley, M., & Mischel, N. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001542 · Cited by 8
“A review of the current literature provided no results that addressed cardiovascular response and its predictive value for response to ketamine or esketamine; however, there are many publications that address the transient increase in blood pressure and heart rate (HR) while receiving subanesthetic ketamine and esketa…”
BackgroundAntidepressant-like effect of CP-101,606: Evidence of mTOR pathway activation
Yu, Q., Guo, X., Song, W., Liang, Z., Wang, Y., Feng, D., Yang, Y., Li, M., & Gao, M. (2023) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2023.103821 · Cited by 8
Ketamine-Associated Bladder Dysfunction—a Review of the Literature
Misra, S. (2018) · Current Bladder Dysfunction Reports · doi:10.1007/s11884-018-0476-1 · Cited by 7
Edem, E. E., Oguntala, O. A., Ikuelogbon, D. A., Nebo, K. E., Fafure, A. A., Akinluyi, E. T., Isaac, G. T., & Kunlere, O. E. (2023) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2023.106370 · Cited by 7
Kwon, J., Sim, W.-S., Hong, J. P., Song, I. S., & Lee, J. Y. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12669 · Cited by 5
Rajagukguk, S., & Lee, T. T. (2019) · Psychosomatics · doi:10.1016/j.psym.2019.09.005 · Cited by 5
The next psychoactive drugs: From imipramine to ketamine
Carrillo, P., Petit, A., Gaillard, R., & Vinckier, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.09.039 · Cited by 5
Xing, H., Liu, X., Zhang, Y., Wu, J., Li, M., Ye, H., Ding, Y., Wang, W., Zheng, Z., & Bao, T. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0151 · Cited by 6
Barbara, A. M., Xie, W., Mahood, Q., & Hamson, A. (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.817 · Cited by 4
Skinner, B. W., Curtis, K. A., & Goodhart, A. L. (2018) · Side effects of drugs annual · doi:10.1016/bs.seda.2018.06.002 · Cited by 6
Schuman, H. D. M., Barkova, S., Mina, R., Deleemans, J. M., Nguyen, T. T.-T. N., & Carlson, L. E. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251370982 · Cited by 4
“44-46 This profile may limit its appropriateness for populations requiring durable, insight-oriented care, such as those with chronic existential distress (eg, demoralization in advanced illness).”
Heinzerling, K. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00009-2 · Cited by 6
Psychotropes du futur : de l’imipramine à la kétamine
Carrillo, P., Petit, A., Gaillard, R., & Vinckier, F. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.09.038 · Cited by 6
Hirsch, D., Reed, J., Naqvi, A., Ngor, A., Dugan, L., Costa, K., Ganasi, R. S., Truman, K. A., Danovitch, I., IsHak, W. W., et al. (2025) · CNS Drugs · doi:10.1007/s40263-025-01248-7 · Cited by 2
“Adverse effects associated with ketamine include dissociative symptoms, transient elevations in blood pressure and heart rate, nausea, and dizziness [60].”
The Role of Ketamine in Treatment-resistant Depression: A Narrative Review
Reddy, A., Patel, S. G., Barik, A. K., Thappa, P., Jangra, K., Kaur, K., Chauhan, R., & Luthra, A. (2024) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2024.00003 · Cited by 4
Back to the Future: Ketamine and Nitrous Oxide in Major Refractory Depression
(2017) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2017.09.00345 · Cited by 2
“A single dose produces antidepressant effects within hours of administration, peak in less than a day, and last up to two weeks [13-15].”
Schwertner, A., Zortéa, M., Torres, F. V., Ramalho, L., Alves, C. F. D. S., Lannig, G., Torres, I. L. D. S., Fregni, F., Gauer, G., & Caumo, W. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00959 · Cited by 3
“Hence, similar effects can be involved in the S-ketamine effect on emotional aspects related to pain and other psychological effects that improve depressive symptoms (Andrade, 2017).”
BackgroundIntravenous Ketamine in Refractory Depression
Gandhi, S., Chaudhari, B., & Chaudhury, S. (2022) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_549_21 · Cited by 2
Ketamine and Electroconvulsive Therapy for Depression
Andrade, C. (2018) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000524 · Cited by 2
Self-citationAnderson, D., Hinchcliffe, J. K., Jackson, M. G., & Robinson, E. S. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.25.684561 · Cited by 2
“Ketamine’s antidepressant utility has mainly been examined in humans through intravenous intervention [51], however the vast majority of ketamine studies (95.3”
InfluentialEgan, D., Ragland, V. E., & Jha, M. K. (2025) · Academic Psychiatry · doi:10.1007/s40596-025-02167-x · Cited by 1
“The off-label use of IV ketamine for depression and other psychiatric conditions has become common [5].”
Mammalian torpor and depressive disorders: a review of evidence for a connection
D’Agati, D. V., & D’Agati, D. C. (2026) · International Review of Psychiatry · doi:10.1080/09540261.2026.2753429 · Cited by 1
Farmakoterapia depresji u pacjentów z zaawansowanymi chorobami
Grabowski, J., & Przybylak, M. (2019) · Palliative Medicine in Practice · doi:10.5603/pmpi.2019.0012 · Cited by 3
Wieczorek, M., Janowska, S., & Gałecki, P. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.10.645 · Cited by 1
Rascón-Martínez, D. M., Fresán, A., Duque-Alarcón, X., Carmona-Alvarado, A., Castellanos-Olivares, A., & Pérez‐Zepeda, M. U. (2022) · Revista Mexicana de Anestesiología · doi:10.35366/106341 · Cited by 2
Gas necrosis and sepsis due to recreational ketamine use
Bezerra, A. S., Vazquez, C. M. P., GUILHERME, A. C. T., Rodrigues, A. B. R., Crivillari, M. B., & Queiroz, W. (2025) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202567009 · Cited by 1
Bajwa, A. A., Ali, S., Khan, S. A., Saleem, N., & Nazir, T. B. (2023) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v73i1.8818 · Cited by 2
Andrade, C. (2019) · Journal of Ect · doi:10.1097/yct.0000000000000567 · Cited by 1
“When administered outside the context of ECT, subanesthetic dosing with ketamine has dramatic antidepressant action.(1) So might the use of ketamine in ECT anesthesia, either in subanesthetic dose or in full anesthetic dose, enhance the antidepressant effect of ECT? This question has been examined in randomized contro…”
BackgroundSelf-citationAndrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17lr11789a
Self-citationPsychopharmacology in Rural Settings
Praharaj, S. K., & Andrade, C. (2019) · Studies in computational intelligence · doi:10.1007/978-981-10-0751-4_17-1
Self-citationSharma, M., & Talati, S. K. (2016) · Indian Journal of Private Psychiatry · doi:10.5005/jp-journals-10067-0041
Chatterjee, D. (2019) · TSpace (University of Toronto) · Cited by 1
Fitri, A. D., Noviana, D., Gunanti, & Suprayogi, A. (2020) · Acta Veterinaria Indonesiana · doi:10.29244/avi.8.3.22-30
Rapid and Sustained Restoration of Astrocytic Functions by Ketamine in Depression Model MicePreprint
Zhang, X., Yang, S., Zhang, Z., Liu, L., Shi, W., Yang, S., Li, S., Cai, X., & Zhou, Q. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3973923
Ketamine for Treatment-Resistant Depression
Madhloom, R. S. (2021) · Mustansiriya Medical Journal · doi:10.4103/mj.mj_15_21
The use of psychoactive substances in the treatment of mental disorders
Karaś-Ruszczyk, K., Groblińska, K., Szczygieł, K., & Samochowiec, J. (2021) · Alcoholism and Drug Addiction · doi:10.5114/ain.2021.111791 · Cited by 2
Perspective Chapter: Ketamine, Depression, and Gender Bias
Alshammari, T. K., Alseraye, S., Al-Rasheed, N. M., Dayel, A. F. B., Alonazi, A. S., Sabhan, J. F. A., & Alshammari, M. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103656
Psychopharmacology in Rural Settings
Praharaj, S. K., & Andrade, C. (2020) · Mental health and illness worldwide · doi:10.1007/978-981-10-2345-3_17
Self-citationDrake, K., Bess, J. D., & Casher, M. I. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108656672.004 · Cited by 1
Traitements psychopharmacologiques
Razavi, D., Reich, M., Farvacques, C., Ronson, A., & Stefos, G. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75811-9.00019-2
Altunöz, S., Baykan, H., & Baykan, Ö. (2023) · Balıkesır Health Sciences Journal · doi:10.53424/balikesirsbd.1276423
Effects of psychedelics on neurogenesis and brain plasticity: A systematic reviewPreprint
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.19.549676
Burhan, A. M., Goveas, D., Thiab, S., & Blair, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-53976-3_14
Tavares, R. F., de Araújo, A. V., Silva, B. C., & Neto, R. C. B. D. F. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i8.15384
CETAMINA COMO INTERVENÇÃO TERAPÊUTICA NA DEPRESSÃO PSICÓTICA E DEPRESSÃO REFRATÁRIA A TRATAMENTO
dos Santos, P. P., Silvério, A. P., Ribeiro, B. C., Rodrigues, L. C., & Nunes, Y. T. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i8.5624
Nist, A. N., Walsh, S. J., & Shahan, T. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06794-y
“…trials, single infusions of ketamine have been shown to reduce depressive symptoms within hours to days (e.g., Berman et al. 2000; Zarate et al. 2006), while producing only limited side-effects that appear to be short-lasting and relatively harmless (e.g., Andrade 2017; Kishi-moto et al. 2016).”
Practical approaches to cardiac clearance in nontraditional clinical scenarios
Kramer, E. F., Ricci, J. F., Shukla, K., Blaker, N. J., Shroff, S., Brand, S. J., Khasawneh, T., Sreekanth, S., & Winchester, D. E. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.07.017
Dong, Y., Tao, B., Xue, X., Feng, C., Ren, Y., Ma, H., Zhang, J., Si, Y., Zhang, S., Liu, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16570088
Martin, E. (2017) · theses.fr (ABES) · doi:10.70675/3f77e643zf119z465fzbc28z20877ecebf8e
Caractérisation neuro-computationnelle de l'humeur : causes et conséquences
Carrillo, P. (2024) · theses.fr (ABES) · doi:10.70675/181aec0cz429dz4bccz83f0za479cbef52f7
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, V., Sujanyal, S. A., Raavi, L., Blumenfeld, S. G., Saleem, F., Bateh, S., Hanson, A., Jena, A., Isha, S., Kunze, K. L., et al. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261438474 · Cited by 1
Metadata
- Authors
- Andrade, C.
- Affiliations
- National Institute of Mental Health and Neurosciences (IN)
- Corresponding author
- Andrade, Chittaranjan
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2017-04-26
- Volume
- 78
- Issue
- 04
- Pages
- e415-e419
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2608784747
- Cited by
- 91
- References
- 0
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 12 · 2018: 17 · 2017: 4
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, depression, treatment-resistant depression, antidepressant efficacy, adverse effects, dissociative effects, psychotomimetic effects, NMDA receptor antagonists, mechanism of action, rapid-acting antidepressants
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.